Abstract: Gefitinib (ZD1839) is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations. Despite initial, often dramatic, clinical responses, the efficacy of gefitinib is inevitably limited by the emergence of acquired resistance, typically occurring within 9 to 14 months of therapy. This comprehensive literature review explores the multifaceted mechanisms of acquired resistance to gefitinib. These mechanisms are broadly categorized into EGFR-dependent (on-target) alterations, most notably the T790M "gatekeeper" mutation, and EGFR-independent (off-target) adaptations, including bypass signaling pathway activation (e.g., MET and HER2 amplification), phenotypic transformations (e.g., small cell lung cancer transformation and epithelial-mesenchymal transition), and epigenetic/microRNA dysregulations. Furthermore, this review discusses the structure-activity relationship underlying gefitinib resistance, current clinical limitations, and future perspectives, including the development of next-generation TKIs, combination therapies, and the integration of liquid biopsies for dynamic resistance monitoring.
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases [1] [5]. The discovery of oncogenic driver mutations in the epidermal growth factor receptor (EGFR) gene fundamentally shifted the treatment paradigm for NSCLC toward personalized, targeted therapies [1] [10]. Gefitinib (ZD1839), developed in the late 1990s, was the first EGFR tyrosine kinase inhibitor (TKI) to enter clinical development [4]. Pivotal clinical trials, such as IDEAL 1 and IDEAL 2, demonstrated its efficacy and tolerability in patients with advanced NSCLC, leading to its approval as a standard first-line treatment for patients harboring common EGFR activating mutations, such as exon 19 deletions and the exon 21 L858R point mutation [1] [4] [5].
While gefitinib provides a favorable and durable treatment response, with response rates up to 80% and a median progression-free survival (PFS) of approximately 9 to 14 months, patients inevitably develop progressive disease due to acquired resistance [1] [4]. The clinical definition of acquired resistance to EGFR-TKIs involves disease progression after an initial objective response or stable disease [1] [5]. Understanding the diverse and complex biological mechanisms driving this acquired resistance is critical for developing subsequent therapeutic strategies and improving long-term patient outcomes.
2. Pharmacological Activity
Gefitinib is an orally active, reversible, small-molecule inhibitor of the EGFR tyrosine kinase [4] [10]. The EGFR is a transmembrane protein that, upon binding with its specific ligands, undergoes homo- or heterodimerization, stimulating its intrinsic intracellular tyrosine kinase activity [5] [10]. This auto-phosphorylation triggers a cascade of downstream signaling pathways, including the RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR, and JAK/STAT pathways, which are crucial for cell proliferation, survival, angiogenesis, and metastasis [4] [5] [10].
Gefitinib exerts its pharmacological activity by competitively binding to the ATP-binding pocket within the kinase domain of the EGFR [2]. In patients with sensitizing EGFR mutations (e.g., L858R or exon 19 deletions), the mutant receptor exhibits a reduced affinity for ATP, which significantly increases the sensitivity and competitive binding efficacy of gefitinib [2]. By blocking ATP binding, gefitinib effectively halts the auto-phosphorylation of the receptor, thereby shutting down the downstream signaling cascades, inducing cell cycle arrest (such as G1 arrest), and promoting apoptosis in EGFR-addicted cancer cells [4] [10].
3. Molecular Mechanism of Action
The mechanisms of acquired resistance to gefitinib are highly heterogeneous and can be broadly classified into EGFR-dependent (on-target) modifications, alternative pathway (off-target) activations, phenotypic transformations, and epigenetic/microRNA regulations [1] [4] [5].
EGFR-Dependent Mechanisms: The most prevalent mechanism, accounting for 50-60% of acquired resistance cases, is the secondary T790M mutation in exon 20 of the EGFR gene [1] [2] [5]. Other less frequent secondary point mutations that confer resistance to gefitinib include D761Y, L747S, and T854A [1] [4] [5].
Alternative Pathway Activation: Cancer cells can bypass EGFR inhibition by activating parallel signaling tracts. MET gene amplification is the most common bypass mechanism, occurring in 5-20% of cases [1] [4] [5]. MET amplification, or the overexpression of its ligand hepatocyte growth factor (HGF), reactivates the PI3K/AKT pathway via ERBB3 transactivation, independent of EGFR [1] [3]. HER2 amplification is another bypass mechanism, found in approximately 10-12% of resistant tumors, which restores downstream signaling and is typically mutually exclusive with the T790M mutation [3] [5]. Additional off-target mechanisms include mutations or amplifications in PIK3CA, BRAF (e.g., V600E), KRAS, and the activation of the AXL receptor tyrosine kinase, IGF1R, and IL-6/JAK/STAT pathways [1] [3] [4] [5].
Phenotypic Transformation: Histological transformation from NSCLC to small cell lung cancer (SCLC) occurs in 3-15% of patients [3] [4]. This transformation is strongly associated with the concurrent inactivation of the RB1 and TP53 tumor suppressor genes [1] [3] [5]. Additionally, epithelial-mesenchymal transition (EMT) contributes to resistance. During EMT, cancer cells lose epithelial markers (e.g., E-cadherin) and acquire a mesenchymal phenotype (e.g., vimentin expression), driven by transcription factors such as Slug, ZEB1, Snail, and TWIST1 [1] [3] [4].
MicroRNA Regulation: Dysregulation of microRNAs (miRNAs) also modulates gefitinib resistance. For instance, the downregulation of miR-133a-3p promotes resistance, which can be reversed by its overexpression targeting SPAG5 [9]. Similarly, miR-483-3p targets integrin beta-3 to inhibit the FAK/Erk pathway, and miR-625-3p targets the AXL receptor; the loss of these miRNAs contributes to the survival and metastasis of gefitinib-resistant cells [9].
4. Structure-Activity Relationship (SAR)
The structure-activity relationship of gefitinib is heavily impacted by the conformational state of the EGFR kinase domain. Gefitinib is designed to fit into the ATP-binding cleft of the active kinase. The emergence of the T790M mutation fundamentally alters this interaction. The T790M mutation involves the substitution of a hydrophilic threonine residue with a bulky, hydrophobic methionine at amino acid position 790 in exon 20 [1] [2]. Because residue 790 is located at the entrance to the hydrophobic pocket of the ATP-binding cleft, it acts as a "gatekeeper" [1] [2].
The introduction of the bulky methionine sidechain causes a conformational change that creates steric hindrance, physically interfering with the ability of gefitinib to bind to the pocket [1] [2]. More importantly, the T790M mutation restores the affinity of the mutant EGFR receptor for ATP to levels comparable to the wild-type receptor. Because gefitinib is a reversible, competitive inhibitor, this increased ATP affinity effectively displaces the drug, drastically reducing its inhibitory potency [1] [2] [5].
5. Current Limitations
The primary limitation of gefitinib therapy is the inevitable development of acquired resistance, which restricts the long-term survival benefits for patients [1] [4]. Identifying the specific resistance mechanism is crucial for subsequent treatment, but this is complicated by spatial and temporal tumor heterogeneity [1] [5]. Different metastatic sites or even different clones within the same primary tumor may harbor distinct resistance mechanisms (e.g., T790M in one clone, MET amplification in another) [1] [5].
While tissue re-biopsy is the gold standard for identifying these mechanisms (especially for detecting histological transformations like SCLC), it is invasive, carries clinical risks, and may not capture the full heterogeneous landscape of the tumor [1] [5]. Furthermore, attempts to overcome resistance using combination therapies with first-generation TKIs have faced significant toxicity hurdles. For example, combining afatinib with cetuximab to overcome resistance resulted in high rates of severe adverse effects, such as grade 3/4 skin rash and diarrhea, limiting its clinical utility [1].
6. Future Perspectives
To address the limitations of gefitinib resistance, the therapeutic landscape has rapidly evolved. The development of third-generation, irreversible EGFR-TKIs, such as osimertinib, has successfully targeted the T790M mutation by forming a covalent bond with the C797 residue, overcoming the steric hindrance and ATP affinity issues associated with gefitinib [1] [2] [5]. Fourth-generation TKIs are currently in preclinical development to address subsequent resistance mutations like C797S [5].
For EGFR-independent resistance, combination strategies are a major focus. Clinical trials are actively investigating the combination of gefitinib or osimertinib with MET inhibitors (e.g., capmatinib, tepotinib, savolitinib) to overcome MET-amplified resistance [1] [3] [7]. Additionally, targeting EMT pathways (e.g., AXL inhibitors, TWIST1 inhibitors) and exploring miRNA-based therapeutics (such as miR-483-3p or miR-625-3p mimics) represent promising preclinical avenues to re-sensitize tumors to gefitinib [3] [9].
Finally, the integration of liquid biopsies (analyzing cell-free DNA/ctDNA) into clinical practice offers a non-invasive method to dynamically monitor the emergence of resistance mutations, capture tumor heterogeneity, and guide timely therapeutic switching before clinical or radiological progression occurs [1] [2] [5].
